AI-generated summary
This review surveys current and emerging treatments for dry age-related macular degeneration, including supplements, drugs, gene and cell therapies, nanotechnology, light-based therapies and artificial intelligence tools. The authors report that AREDS/AREDS2 supplements slow progression but cannot reverse retinal damage, and that further clinical trials are needed to confirm the newer approaches.
- Who or what was studied
- unclear
- Limits stated in the abstract
- The abstract describes a literature review and states that clinical trials are still needed to optimize these strategies and assess long-term outcomes.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on rjo.ro.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Age-related macular degeneration, Low-level laser therapy, Oxidative stress, Inflammation, Mitochondria, Phototherapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.